Search results for "Progesterone receptor"

showing 10 items of 56 documents

Effect of mifepristone on the transcriptomic signature of endometrial receptivity

2018

Study question How does a single dose of mifepristone on Day 2 after the LH peak (LH + 2) affect the endometrial receptivity transcriptome as assessed by the receptive signature established by the endometrial receptivity analysis (ERA)? Summary answer A single dose of mifepristone on day LH + 2 renders the endometrium non-receptive by altering the transcriptome associated with endometrial receptivity. What is known already Mifepristone is a progesterone receptor modulator that has been shown to alter endometrial receptivity. The ERA is a computational predictor that utilizes gene expression data of 248 genes from next generation sequencing to identify endometrial receptivity status. Study d…

0301 basic medicineBiologyReal-Time Polymerase Chain ReactionEndometriumAndrologyTranscriptomeEndometrium03 medical and health sciences0302 clinical medicineGlucocorticoid receptorProgesterone receptorFollicular phaseGene expressionHumansMedicineEmbryo ImplantationRegulation of gene expression030219 obstetrics & reproductive medicinebusiness.industryRehabilitationObstetrics and GynecologyMifepristoneMifepristone030104 developmental biologymedicine.anatomical_structureGene Expression RegulationReproductive MedicineCase-Control StudiesFemaleEndometrial receptivityReceptors ProgesteroneTranscriptomebusinessmedicine.drugHuman Reproduction
researchProduct

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

2019

No luminal; Subtipus intrínsec; Càncer de mama No luminal; Subtipo intrínseco; Cáncer de mama Non-luminal; Intrinsic subtype, Breast cancer Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estr…

0301 basic medicineCancer Researchmedicine.medical_specialtyintrinsic subtype:Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]:Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation Neoplastic [PHENOMENA AND PROCESSES]medicine.medical_treatmentEstrogen receptor:fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica [FENÓMENOS Y PROCESOS]:aminoácidos péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos [COMPUESTOS QUÍMICOS Y DROGAS]lcsh:RC254-282Gastroenterology03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerMama - CàncerInternal medicineRegulació genèticaProgesterone receptorMedicinePAM50Original Research:neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES]Chemotherapynon-luminalbusiness.industry:Amino Acids Peptides and Proteins::Proteins::Receptors Cytoplasmic and Nuclear::Receptors Steroid::Receptors Estrogen [CHEMICALS AND DRUGS]lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyEstrògens - ReceptorsOncologyHormone receptor030220 oncology & carcinogenesisCohortgene expressionBiomarker (medicine)ImmunohistochemistrybusinessFrontiers in Oncology
researchProduct

NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers.

2017

Breast cancer continues to cause significant burden in global health morbidity and mortality. Triple-negative breast cancers (TNBCs) are highly aggressive with poor prognosis and are characterized by lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (Her-2). TNBCs are often resistant to cytotoxic chemotherapy and pose major difficulty in achieving personalized medicine due to their molecular heterogeneity. There is increasing evidence that the aberrant activation of nuclear factor (NF)-κB signaling is a frequent characteristic of TNBCs. We evaluated the effects of different potential NF-κB inhibitors, such as bisindolylmaleimide I (BI…

0301 basic medicineCurcuminEstrogen receptorTriple Negative Breast NeoplasmsPharmacologydiagnostics drug targets NF-kB signaling personalized medicine triple-negative breast cancerBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerCell Line TumorMG132Progesterone receptorGeneticsmedicineGene silencingHumansPrecision MedicineMolecular BiologyTriple-negative breast cancerbusiness.industryCyclohexanonesNF-kappa BCancermedicine.disease030104 developmental biologychemistry030220 oncology & carcinogenesisBenzamidesProteasome inhibitorCancer researchMolecular MedicineFemalebusinessBiotechnologymedicine.drugSignal TransductionOmics : a journal of integrative biology
researchProduct

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

2021

Breast cancer (BC) heterogeneity is composite in nature, with a wide variety of factors concurring to define several pathological entities, which differ by clinical presentation, pathologic features, therapy administered, and inherent outcomes1. Additional sources of breast cancer heterogeneity may raise during the disease course. In BC patients whose disease was initially diagnosed in the early stage and subsequently progressed with metastatic involvement of one single or multiple site/s, the molecular characteristics of metastatic lesions do not necessary mimic those of the disease initially diagnosed. A well-depicted molecular landscape is crucial for subtype definition, prognostic evalu…

0301 basic medicineOncologyCancer therapyReceptor ErbB-2medicine.medical_treatmentAdo-Trastuzumab Emtansineprogesterone receptorSettore MED/060302 clinical medicinehuman epidermal growth factor receptor 2 (HER2)Antineoplastic Combined Chemotherapy ProtocolsestrogenNeoplasm Metastasisskin and connective tissue diseasesMultidisciplinaryBrain NeoplasmsQRMiddle AgedPrognosisMetastatic breast cancerNeoplasm Metastasi030220 oncology & carcinogenesisMedicineFemalePertuzumabmetastatic breast cancerReceptors ProgesteroneBreast NeoplasmHER2 positivitymedicine.drugHumanAdultmedicine.medical_specialtymedicine.drug_classSciencetrastuzumab-emtansineBreast Neoplasmsmetastatic breast cancer; HER2 positivity; cancerArticleDisease-Free SurvivalBrain Neoplasm03 medical and health sciencesBreast cancerbreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicineProgesterone receptormedicineHumanscancerbreast cancer; human epidermal growth factor receptor 2 (HER2); pertuzumab; trastuzumab-emtansine; estrogen; progesterone receptorneoplasmsAgedChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancermedicine.diseaseHER2-positiveBreast cancer; oncology; radiotherapy; chemotherapy; HER2Radiation therapy030104 developmental biologyEstrogenbusinessprognostic relevance
researchProduct

microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status—A Pilot Study

2020

Estrogen (ER) and progesterone (PgR) receptors and HER2 are crucial in the assessment of breast cancer specimens due to their prognostic and predictive significance. Single hormone receptor-positive breast cancers are less common and their clinical course is less favorable than ER(+)/PgR(+) tumors. Their molecular features, especially microRNA (miRNA) profiles, have not been investigated to date. Tumor specimens from 36 chemonaive breast cancer patients with known ER and PgR status (18 ER(+)/PgR(&minus

0301 basic medicineendocrine systemmedicine.drug_classClinical BiochemistryEstrogen receptorBiologyArticleprogesterone receptor03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerHER2Progesterone receptormedicineReceptorskin and connective tissue diseaseslcsh:R5-920microRNAMicroRNA Expression Profilemedicine.diseaseFold change030104 developmental biologyEstrogenHormone receptor030220 oncology & carcinogenesisbreast cancer; estrogen receptor; progesterone receptor; HER2; microRNACancer researchlcsh:Medicine (General)hormones hormone substitutes and hormone antagonistsestrogen receptorDiagnostics
researchProduct

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

2018

Abstract Background Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study ( NCT00129922 ). Methods Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall surv…

Adult0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtyPaclitaxelBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsProgesterone receptormedicineHumansPAM50Single receptor positiveskin and connective tissue diseasesReceptorCyclophosphamideAgedEpirubicinProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesHormone receptor positivebusiness.industryIncidence (epidemiology)Hazard ratioLuminal aMiddle Agedmedicine.disease030104 developmental biologyClinical Trials Phase III as TopicReceptors EstrogenOncologyIntrinsic subtypesHormone receptor030220 oncology & carcinogenesisFemaleFluorouracilReceptors ProgesteroneTranscriptomebusinesshormones hormone substitutes and hormone antagonistsHormoneEuropean Journal of Cancer
researchProduct

Expression of hormonal receptors in osteosarcomas of the jaw bones: clinico-pathological analysis of 21 cases

2013

Background: Sexual hormones have an important role in many hormone-dependant tumors like breast and prostate carcinomas, and also a relationship has been found with bone metabolism and bone tumors. Some studies have demonstrated that the expression of hormonal receptors (HR) in osteosarcomas (OS) of long bones is associated with gender, histological grade, histological type, and possibly may be connection with pathogenesis and evolution. However, to our knowledge there are no studies of HR in osteosarcomas of craniofacial bones (OS-CF). Objectives: To assess the expression of hormonal receptors in OS-CF. Material and Methods: Twenty one cases of OS-CF were included in this study. Clinical o…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.drug_classEstrogen receptorOdontologíaYoung AdultProgesterone receptormedicineHumansCraniofacialReceptorGeneral DentistryAgedOsteosarcomaOral Medicine and Pathologybusiness.industryResearchMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseJaw NeoplasmsCiencias de la saludAndrogen receptorReceptors EstrogenOtorhinolaryngologyReceptors AndrogenEstrogenUNESCO::CIENCIAS MÉDICASOsteosarcomaFemaleSurgeryReceptors ProgesteronebusinessProgressive disease
researchProduct

Immunohistochemical expression of estrogens and progesterone receptors in carcinoma ex pleomorphic adenoma-undifferentiated and adenocarcinoma types.

2009

Cancer of the salivary gland is one of the common cancers in the head and the neck regions. This type of cancer develops in the minor and the major salivary glands, and it sometimes metastasizes to other organs, particularly the lung. Morphologic mimicry and similarity in the expression of steroid hormone receptors between salivary gland tumors and breast tumors are well-known phenomena and are occasionally debated in the field of surgical pathology. The expression of sex hormone receptors in some tumors suggests a role for these receptors in tumor pathogenesis and therapy. Previous studies of the expression of estrogens and progesterone receptors in salivary gland tumors have reported conf…

AdultMalePathologymedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdenoma PleomorphicAdenocarcinomaPleomorphic adenomaNeoplasms Multiple PrimaryMajor Salivary GlandProgesterone receptormedicineHumansReceptorGeneral DentistryAgedAged 80 and overbusiness.industrySex hormone receptorMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Salivary Gland NeoplasmsImmunohistochemistrySteroid hormoneCarcinoma ex pleomorphic adenomaOtorhinolaryngologyReceptors EstrogenUNESCO::CIENCIAS MÉDICASAdenocarcinomaSurgeryFemalebusinessReceptors ProgesteroneMedicina oral, patologia oral y cirugia bucal
researchProduct

Correlations of female steroid hormone receptors with histologic features in meningiomas.

1991

A series of 39 samples were obtained from meningiomas in 28 patients in order to investigate the relationships of the oestrogen receptor (OER) and progesterone receptor (PR) with the tumoural subtype and some histological features. Twenty-one samples were positive (greater than 10 fmole/mg protein), 7 were OER-PR-negative, and 1 was positive in both receptors. Twenty-two samples were considered as syncitial, 7 transitional, 7 fibroblastic and 3 angioblastic. The histological subtype was not found to be significantly related to the presence or absence of PR. Relations were not observed between the progestin receptor and the following histological parameters: cellular pattern, cell density, n…

AdultMalemedicine.medical_specialtyNecrosisPsammoma bodymedicine.drug_classmedicine.medical_treatmentMitosisMeningiomaNecrosisInternal medicineProgesterone receptormedicineMeningeal NeoplasmsHumansReceptorAgedbusiness.industryHistologyMiddle Agedmedicine.diseaseSteroid hormoneEndocrinologyReceptors EstrogenEstrogenSurgeryFemaleNeurology (clinical)medicine.symptombusinessMeningiomaReceptors ProgesteroneActa neurochirurgica
researchProduct

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

2008

Abstract Purpose: Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. Experimental Design: Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression. Results: Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disea…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyNeoplasms Hormone-DependentEstrogen receptorBreast Neoplasmschemistry.chemical_compoundDrug Delivery SystemsBreast cancerAntigens NeoplasmInternal medicineProgesterone receptorBiomarkers TumormedicineHumansAgedAged 80 and overbusiness.industryHazard ratioCancerEpithelial cell adhesion moleculeMiddle AgedEpithelial Cell Adhesion MoleculePrognosismedicine.diseaseOncologychemistryHormone receptorLymphatic MetastasisFemaleBreast diseasebusinessCell Adhesion MoleculesClinical Cancer Research
researchProduct